Sarah A Sayer (1)
Background: Acute interstitial nephritis causes blood flow to be impaired, this ultimately leads to inflammation and edema in the renal tubules and tissues, this decreases the glomerular filtration rate (GFR). Early detection and treatment of the disease can mitigate the progression of renal failure. To investigate the potential for IL-39 and IL-37 to be used in the diagnosis of acute interstitial nephritis, this study sought to measure the levels ofinflammatory markers, interstitial nephritis, and antioxidant agents in patients with acute interstitial nephritis using receiver operating characteristic (ROC) graphs.Methods: The investigation had 25 patients and 25 controls that were between the ages of 40 and 65 during the years 2023 and 2024.Results: The outcomes demonstrated that the concentrations of urea, creatinine, C-reactive protein (CRP), IL-39, IL-37, and MDA in the patient's blood were significantly greater than those in the control's. However, the concentrations of albumin, GSH, and SOD in the blood of the patients were significantly lower than those of the controls. Additionally, the ROC curve demonstrated that the concentrations of MDA,TNF-α,GSH,SOD,IL-39, and IL-37 were effective at differentiating patients with acute tubular necrosis from healthy individuals. Overall, inflammation has been linked to increased oxidative stress, the release of proinflammatory cytokines, and the development of an inflammation state. As a result, understanding the total disease burden and adding extra criteria will facilitate the early detection or preemptive risk assessment for each patient. This will facilitate future investigations of the pathophysiology of diseases in diagnosis, prognosis, and treatment.
Highlight
IL-39 and IL-37 show strong diagnostic potential for acute interstitial nephritis.
Patients exhibited higher inflammation and oxidative stress markers, with reduced antioxidant levels.
ROC analysis confirmed several biomarkers as effective differentiators from healthy controls.
Keywords: Acute Interstitial Nephritis, IL-39, IL-37, Oxidative Stress, ROC Curve
[1] E. Joyce, P. Glasner, S. Ranganathan, and A. Swiatecka-Urban, “Tubulointerstitial Nephritis: Diagnosis, Treatment, and Monitoring,” Pediatric Nephrology, vol. 32, no. 4, pp. 577–587, Apr. 2017.
[2] D. G. Moledina et al., “Urine Interleukin-9 and Tumor Necrosis Factor-α for Prognosis of Human Acute Interstitial Nephritis,” Nephrology Dialysis Transplantation, vol. 36, no. 10, pp. 1851–1858, 2021.
[3] M. Haas, B. H. Spargo, E. J. Wit, and S. M. Meehan, “Etiologies and Outcome of Acute Renal Insufficiency in Older Adults: A Renal Biopsy Study of 259 Cases,” American Journal of Kidney Diseases, vol. 35, no. 3, pp. 433–447, Mar. 2000.
[4] C. C. Nast, “Medication-Induced Interstitial Nephritis in the 21st Century,” Advances in Chronic Kidney Disease, vol. 24, no. 2, pp. 72–79, Mar. 2017.
[5] K. Hosohata, “Role of Oxidative Stress in Drug-Induced Kidney Injury,” International Journal of Molecular Sciences, vol. 17, no. 11, p. 1826, Nov. 2016.
[6] Y.-Y. Gu, X.-S. Liu, X.-R. Huang, X.-Q. Yu, and H.-Y. Lan, “TGF-β in Renal Fibrosis: Triumphs and Challenges,” Future Medicinal Chemistry, vol. 12, no. 9, pp. 853–866, May 2020.
[7] A. G. Stewart, B. Thomas, and J. Koff, “TGF-β: Master Regulator of Inflammation and Fibrosis,” Respirology, vol. 23, no. 12, pp. 1096–1097, Dec. 2018.
[8] X.-M. Meng, D. J. Nikolic-Paterson, and H.-Y. Lan, “TGF-β: The Master Regulator of Fibrosis,” Nature Reviews Nephrology, vol. 12, no. 6, pp. 325–338, Jun. 2016.
[9] J.-H. Gu et al., “Serum Level of Interleukin-35 as a Potential Prognostic Factor for Gastric Cancer,” Asia-Pacific Journal of Clinical Oncology, vol. 17, no. 1, pp. 52–59, 2021.
[10] X. Qiu, X. Wang, Y. Song, and L. Chen, “Plasma Level of Interleukin-35 as an Independent Prognostic Indicator in Hepatocellular Carcinoma,” Digestive Diseases and Sciences, vol. 61, no. 12, pp. 3513–3521, Dec. 2016.
[11] Y. Ma et al., “IL-6, IL-8 and TNF-α Levels Correlate with Disease Stage in Breast Cancer Patients,” Advances in Clinical and Experimental Medicine, vol. 26, no. 3, pp. 421–426, 2017.
[12] M. Povar-Echeverría et al., “Interleukin-6 Could Be a Potential Prognostic Factor in Ambulatory Elderly Patients with Stable Heart Failure: Results from a Pilot Study,” Journal of Clinical Medicine, vol. 10, no. 3, p. 504, 2021.
[13] G. M. Gager et al., “Interleukin-6 Level Is a Powerful Predictor of Long-Term Cardiovascular Mortality in Patients with Acute Coronary Syndrome,” Vascular Pharmacology, vol. 135, p. 106806, Feb. 2020.
[14] P. Zhou et al., “Increased Serum Interleukin-6 Level as a Predictive Biomarker for Atrial Fibrillation: A Systematic Review and Meta-Analysis,” Revista Portuguesa de Cardiologia (English Edition), vol. 39, no. 12, pp. 723–728, 2020.
[15] E. Y.-C. Ting, A. C. Yang, and S.-J. Tsai, “Role of Interleukin-6 in Depressive Disorder,” International Journal of Molecular Sciences, vol. 21, no. 6, p. 2194, Mar. 2020.
[16] R. Balasa et al., “Assessment of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-Beta1 Serum Titers in Relapsing Remitting Multiple Sclerosis Patients Treated with Avonex, Possible Biomarkers for Treatment Response,” CNS & Neurological Disorders - Drug Targets, vol. 16, no. 1, pp. 93–101, 2017.
[17] D. He, M. Liu, and B. Liu, “Interleukin-35 as a New Biomarker of Renal Involvement in Lupus Nephritis Patients,” Tohoku Journal of Experimental Medicine, vol. 244, no. 4, pp. 263–270, 2018.
[18] T. Tabata, N. Sugiyama, Y. Otsuki, and Y. Kondo, “Interleukin-24 Is a Novel Diagnostic Biomarker for the Severity of Acute Kidney Injury,” Medical Molecular Morphology, vol. 53, no. 2, pp. 115–123, Jun. 2020.
[19] J. H. Greenberg et al., “Interleukin-6 and Interleukin-10 as Acute Kidney Injury Biomarkers in Pediatric Cardiac Surgery,” Pediatric Nephrology, vol. 30, no. 9, pp. 1519–1527, Sep. 2015.
[20] V. L. Ferreira, H. H. L. Borba, A. D. F. Bonetti, L. P. Leonart, and R. Pontarolo, “Cytokines and Interferons: Types and Functions,” in Cytokines, IntechOpen, London, UK, 2018.
[21] C. Brocker, D. Thompson, A. Matsumoto, D. W. Nebert, and V. Vasiliou, “Evolutionary Divergence and Functions of the Human Interleukin (IL) Gene Family,” Human Genomics, vol. 5, p. 30, 2010.
[22] J.-M. Zhang and J. An, “Cytokines, Inflammation, and Pain,” International Anesthesiology Clinics, vol. 45, no. 2, pp. 27–37, 2007.
[23] V. Andrade-Oliveira, O. Foresto-Neto, I. K. M. Watanabe, R. Zatz, and N. O. S. Câmara, “Inflammation in Renal Diseases: New and Old Players,” Frontiers in Pharmacology, vol. 10, p. 1192, Oct. 2019.
[24] T. Petreski, N. Piko, R. Ekart, R. Hojs, and S. Bevc, “Review on Inflammation Markers in Chronic Kidney Disease,” Biomedicines, vol. 9, no. 2, p. 182, Feb. 2021.
[25] X. Wang et al., “A Novel IL-23p19/Ebi3 (IL-39) Cytokine Mediates Inflammation in Lupus-Like Mice,” European Journal of Immunology, vol. 46, no. 6, pp. 1343–1350, Jun. 2016.
[26] Y. Luo et al., “Elevated Serum IL-39 in Patients with ST-Segment Elevation Myocardial Infarction Was Related with Left Ventricular Systolic Dysfunction,” Biomarkers in Medicine, vol. 11, no. 6, pp. 419–426, Jun. 2017.
[27] M. G. Yang, S. Tian, Q. Zhang, et al., “Elevated Serum Interleukin-39 Levels in Patients with Neuromyelitis Optica Spectrum Disorders Correlated with Disease Severity,” Multiple Sclerosis and Related Disorders, vol. 46, p. 102430, Nov. 2020.
[28] Y. Li, L. Gong, X. Weng, X. Pan, C. Liu, and M. Li, “Interleukin-39 Exacerbates Concanavalin A-Induced Liver Injury,” Immunopharmacology and Immunotoxicology, vol. 43, no. 1, pp. 94–99, Jan. 2021.
[29] X. Li, T. He, C. Liu, S. Qin, T. Xiao, and X. Wang, “IL-37 Ameliorates Renal Fibrosis by Restoring CPT1A-Mediated Fatty Acid Oxidation in Diabetic Kidney Disease,” Kidney Diseases, vol. 9, no. 2, pp. 104–117, 2023.
[30] S. Taguchi, K. Azushima, T. Yamaji, et al., “Effects of Tumor Necrosis Factor-α Inhibition on Kidney Fibrosis and Inflammation in a Mouse Model of Aristolochic Acid Nephropathy,” Scientific Reports, vol. 11, p. 23587, 2021.
[31] H. Sies, C. Berndt, and D. P. Jones, “Oxidative Stress,” Annual Review of Biochemistry, vol. 86, pp. 715–748, 2017.
[32] A. K. Zaid and S. A. Sayer, “Association of Abnormal Levels of Serum Interleukin-33, Interleukin-23 with Oxidant-Antioxidants Status in Patients with Acute Liver Failure,” Journal of Scientific Research and Reports, vol. 9, pp. 94–99, 2022.
[33] E. J. Ramos-González, O. K. Bitzer-Quintero, G. Ortiz, J. J. Hernández-Cruz, and L. J. Ramírez-Jirano, “Relationship Between Inflammation and Oxidative Stress and Its Effect on Multiple Sclerosis,” Neurología (English Edition), 2021.